Category: Press Releases

Publication of cardiac ATTR amyloidosis diagnosis guidelines
ARC-supported consensus best practices guidelines for the diagnosis of cardiac ATTR amyloidosis published in the journal of the American Heart Association, Circulation:Heart Failure. (more…)
Read More
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More
Advancing Amyloidosis: Roadmap for Research
FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)
Read More
Tafamidis under review
Tafamidis accepted for FDA Review in 2019
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Read More
NICE appraisal for amyloidosis
NICE issue initial negative decisions on inotersen and patisiran
The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization